Helixgate https://validator.w3.org/feed/docs/rss2.html Dissecting Chinese trial strategy in wake of deaths Enveda’s exercise-simulating obesity tablet clears early clinical test 2026 IPO stock tracker: How newly public biotechs are performing She grew up unvaccinated. Now she’s a leading voice for science — and empathy Leadership Lab: The one person executives need by their side Physician group sues Trump administration over dietary guidelines process  Takeda leads wave of orexin drugs with potential to upend narcolepsy market With China rising, Hong Kong builds bridge to biotech innovation STAT+: Trump expected to pick White House adviser Heidi Overton to lead FDA High-throughput synthesis of DNA fragments by molecular self-assembly of overlapping oligonucleotides Massive-scale parallel gene synthesis with oligonucleotide hybridization Fauci adviser David Morens pleads guilty to avoiding records requests, conspiracy to defraud government Trump administration sued over visa time limit that would affect grad students, postdocs Header STAT+: The White House declares ‘promises made, promises kept’ on lowering drug prices. Nice try Embedding Regulatory Strategy in Cell and Gene Therapy Development STAT+: Real-world psilocybin data suggest need for close monitoring STAT+: Leaders of Mass General, Dana-Farber among hospital execs who got big raises in 2024 Home Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy lifting BioMarin acquires experimental drug for rare bone disorder in $275M deal AstraZeneca’s win in lung cancer; Sandoz inks a China deal Calla Lily Clinical Care join Wellcome Leap’s antibiotics programme Exercise-Boosting Molecule May Help Improve Muscle Health in Type 2 Diabetes Merck and Sarah Cannon team up to boost oncology trial efficiency Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug Rebounding biotech funds expected to spur CDMO growth within year Regeneron ends eye disease study due to antibody’s safety profile Amylyx’s bet on a GLP-1 blocker pays off Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass Opinion: In parts of the world, antibiotic overuse isn’t the problem — underuse is Assessing shared failures with AI is key to cell and gene therapy’s evolution Editor’s pick: Dispatch Biotherapeutics Albumin-Fused Antibodies May Reduce Fetal Exposure to Therapeutics Malaria Mosquito Bites Turned Into Immune Boosters in New Chemovaccination Strategy STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise University of Rhode Island Wins Grant to Study Cerebral Amyloid Angiopathy Prevalent in Alzheimer’s Patients The Microbiome Field Enters Its Next Chapter Pharma Races to Scale AI as Billions Flow into Drug Discovery Argenx jumps on Phase 3 data for blockbuster Vyvgart EyePoint plummets on pivotal data for main drug Roundup: Removing Impurities from Biomanufacturing STAT+: The IRS is probing UnitedHealth, and a private equity slowdown EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race Regeneron ends eye disease trial for anti-CD3 antibody following safety review STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit